Together with NANOG and SOX2, OCT3/4 is widely regarded as marker of cancer stem cells, and higher expression of OCT3/4 has been proven to indicate worse clinical outcomes in most cancer types, i.e., more aggressive tumors, short overall survival and chemoresistance (Ling et al., 2012). This evidence concerns the gene SOX2 and cancer.